All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-09-01T14:55:38.000Z

Published case study – Primary refractory DLBCL with brain parenchyma achieving complete remission with CAR T-cell therapy

Sep 1, 2017
Share:

Bookmark this article

On 24th August 2017, in a Letter to the Editor of the New England Journal of Medicine, Jeremy S. Abramson from Massachusetts General Hospital Cancer Center, Boston, MA, USA, et al. published a case report of a female patient, 68 years of age, with Diffuse Large B-Cell Lymphoma (DLBCL) refractory to intensive infusional chemotherapy, DA-EPOCH-R, and four other lines of treatment, including an intermediate-intensity allogeneic Stem Cell Transplant (allo-SCT) from an 8/8 HLA-matched unrelated donor.

Key Highlights:

  • Germinal center subtype, BCL2 rearrangement, multiple copies of MYC and BCL6
  • Enrolled in a phase I clinical trial of JCAR017 (NCT02631044); received lymphodepleting fludarabine–cyclophosphamide before CAR T-cell therapy
  • No CRS, neurotoxic effects, or GvHD
  • One month later, brain MRI confirmed complete remission
  • Two months later, restaging identified recurrent subcutaneous disease
  • After incisional biopsy, visible tumor receded with no further treatment
  • PET-CT 1 month after biopsy confirmed complete remission
  • Pharmacokinetic testing showed marked expansion of CAR T-cells
  • Ongoing remission at 12 months

The authors emphasized that they identified anti-CD19 CAR T-cells in cerebrospinal fluid, which confirms the ability of cells to cross the blood-brain barrier. Lastly, this case also confirms the ability of anti-CD19 CAR T-cells to re-expand in vivo months after initial infusion and can re-exert their anti-tumor activity; something in the biopsy procedure triggered CAR T-cell re-expansion and activation.

  1. Abramson J.S. et al. Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. New England Journal of Medicine. 2017 Aug 24;377(8):783-784. DOI: 10.1056/NEJMc1704610.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox